China Universal Asset Management Co. Ltd. Has $109,000 Stock Holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

China Universal Asset Management Co. Ltd. lifted its holdings in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 63.7% in the third quarter, Holdings Channel.com reports. The institutional investor owned 69,527 shares of the biopharmaceutical company’s stock after acquiring an additional 27,058 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Lexicon Pharmaceuticals were worth $109,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Lexicon Pharmaceuticals by 34.7% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 731,138 shares of the biopharmaceutical company’s stock worth $1,148,000 after acquiring an additional 188,239 shares during the last quarter. Compagnie Lombard Odier SCmA lifted its stake in Lexicon Pharmaceuticals by 6.4% in the 3rd quarter. Compagnie Lombard Odier SCmA now owns 100,000 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 6,000 shares during the last quarter. SG Americas Securities LLC boosted its position in Lexicon Pharmaceuticals by 107.6% in the third quarter. SG Americas Securities LLC now owns 46,090 shares of the biopharmaceutical company’s stock valued at $72,000 after buying an additional 23,893 shares in the last quarter. Nantahala Capital Management LLC bought a new stake in shares of Lexicon Pharmaceuticals during the second quarter worth $3,871,000. Finally, Point72 Asset Management L.P. increased its holdings in shares of Lexicon Pharmaceuticals by 605.2% during the second quarter. Point72 Asset Management L.P. now owns 4,121,191 shares of the biopharmaceutical company’s stock worth $6,924,000 after buying an additional 3,536,805 shares in the last quarter. 74.70% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Needham & Company LLC restated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Wednesday. StockNews.com upgraded Lexicon Pharmaceuticals to a “sell” rating in a report on Tuesday, July 9th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Lexicon Pharmaceuticals in a report on Wednesday. Finally, Leerink Partners set a $6.00 target price on shares of Lexicon Pharmaceuticals and gave the stock an “outperform” rating in a report on Friday, October 18th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, Lexicon Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $8.00.

Lexicon Pharmaceuticals Trading Down 3.9 %

Shares of LXRX stock opened at $1.95 on Friday. The stock has a 50-day moving average of $1.73 and a 200-day moving average of $1.77. The company has a current ratio of 11.51, a quick ratio of 11.49 and a debt-to-equity ratio of 0.41. The stock has a market cap of $480.16 million, a price-to-earnings ratio of -2.50 and a beta of 1.28. Lexicon Pharmaceuticals, Inc. has a 1-year low of $0.92 and a 1-year high of $3.73.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.01. Lexicon Pharmaceuticals had a negative net margin of 5,509.34% and a negative return on equity of 105.38%. The firm had revenue of $1.65 million during the quarter, compared to analyst estimates of $2.74 million. During the same quarter last year, the business earned ($0.22) EPS. On average, equities research analysts forecast that Lexicon Pharmaceuticals, Inc. will post -0.69 earnings per share for the current year.

Lexicon Pharmaceuticals Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.